Palmatine suppresses glutamine-mediated interaction between pancreatic cancer and stellate cells through simultaneous inhibition of survivin and COL1A1

Abstract

Reciprocal interaction between pancreatic stellate cells (PSCs) and cancer cells (PCCs) in the tumor microenvironment (TME) promotes tumor cell survival and progression to lethal, therapeutically resistant pancreatic cancer. The goal of this study was to test the ability of Palmatine (PMT) to disrupt this reciprocal interaction in vitro and examine the underlying mechanism of interaction. We show that PSCs secrete glutamine into the extracellular environment under nutrient deprivation. PMT suppresses glutamine-mediated changes in GLI signaling in PCCs resulting in the inhibition of growth and migration while inducing apoptosis by inhibition of survivin. PMT-mediated inhibition of (glioma-associated oncogene 1) GLI activity in stellate cells leads to suppression (collagen type 1 alpha 1) COL1A1 activation. Remarkably, PMT potentiated gemcitabine’s growth inhibitory activity in PSCs, PCCs and inherently gemcitabine-resistant pancreatic cancer cells. This is the first study that shows the ability of PMT to inhibit growth of PSCs and PCCs either alone or in combination with gemcitabine. These studies warrant additional investigations using preclinical models to develop PMT as an agent for clinical management of pancreatic cancer.

Inhibition of PTP1B blocks pancreatic cancer progression by targeting the PKM2/AMPK/mTOC1 pathway

“…Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal cancers in the world with the worst prognosis, and its incidence has increased in recent years 1 . To date, the rate of pancreatic cancer incidence nearly equals its mortality due to diagnosis at later stage and the lack of early detection markers 2 . According to an estimate by the American Cancer Society, PDAC will be the second leading cause of cancer-related death in the USA by 2030 3 .…”

Palmatine: A review of pharmacological properties and pharmacokinetics

“…After separate use of PLT and gemcitabine, their IC 50 values were 219.04 and 25 μM, respectively. But when used them simultaneously, the single dose decreased to 73.01 and 0.1 μM analogously for PLT and gemcitabine (Chakravarthy et al, ).…”

Therapeutic strategies for targeting telomerase in cancer

“…Here, we collect natural telomerase inhibitors reported in the literature and summarize their telomerase inhibition effects, structures, possible mechanisms, and provide references for pharmaceutical chemists searching for suitable lead compounds. Table and Figures and show natural products and chemical structures that target the telomere elongation process …”

“…In addition to Berberine, other alkaloids (palmatine ( 51 ) and sanguinarine ( 52 )) also promote the formation and stability of G4. They have been studied further as lead compounds for G4 stabilizers …”

“…Pristimerins ( 55 ) is a highly reversible monoacylglycerol lipase inhibitor that belongs to quinone methyl triterpenoids with broad biological activities. The studies found that it has antiproliferative effects on a variety of tumor cell lines (multiple myeloma, prostate cancer, lung cancer, cervical cancer, and breast cancer) . Deeb et al reported that it inhibits telomere elongation and induces apoptosis, which may be caused by the reduction in the transcription factors and nuclear factor κB associated with the expression of hTERT.…”